All In Biotech

Drug Trial Radar · NCT07281950

Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)

Dry Eye Surveys to Evaluate Acoltremon in Real World Treatment (DESERT)

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Center for Sight Las VegasAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Dry eye disease (DED) is a common, chronic and multifactorial disease of the ocular surface presenting with signs and symptoms of ocular discomfort, visual disturbance and fluctuation, tear film instability, ocular surface inflammation and damage. It significantly affects patients' quality of life and is one of the most frequent reasons for visits to eye care providers. Many patients remain symptomatic in real-world settings despite current pharmacologic therapeutic options available. As symptoms often lag behind ocular signs, a 3 month study with multiple time points has been designed to assess short term and mid-term symptomatic changes. This study will use Dry Eye Surveys to evaluate Acoltremon in Real World Settings to help understand its real world effectiveness and potential to improve symptoms in dry eye patients.

Conditions

  • Dry Eye Disease (DED)

Interventions

  • acoltremon 0.003%Drug

    single arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. • Mean Change in SPEED questionnaire score at 1 month (day 30 ± 3 days)Time frame: Mean Change in SPEED questionnaire score at 1 month (day 30 ± 3 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Sight

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.